Synairgen (LON:SNG) Hits New 12-Month Low – Here’s Why

Synairgen plc (LON:SNG) shares reached a new 52-week low on Friday . The stock traded as low as GBX 1.81 ($0.02) and last traded at GBX 2 ($0.02), with a volume of 3416760 shares. The stock had previously closed at GBX 1.99 ($0.02).

Synairgen Price Performance

The stock has a market capitalization of £4.03 million, a P/E ratio of -66.67 and a beta of -2.23. The business’s 50 day simple moving average is GBX 3.56 and its two-hundred day simple moving average is GBX 3.94. The company has a quick ratio of 6.35, a current ratio of 6.77 and a debt-to-equity ratio of 0.09.

Synairgen Company Profile

Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on lung viral defence in asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease.

Synairgen is conducting a double blind, placebo-controlled clinical trial in COVID-19 patients (SG016).